Banco Bilbao Vizcaya Argentaria S.A. Has $2.32 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Banco Bilbao Vizcaya Argentaria S.A. trimmed its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 28.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,219 shares of the company's stock after selling 5,554 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Zoetis were worth $2,315,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in ZTS. Callahan Advisors LLC lifted its holdings in Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock valued at $2,135,000 after purchasing an additional 6,221 shares in the last quarter. CIBC Asset Management Inc lifted its position in Zoetis by 24.1% during the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock worth $38,617,000 after buying an additional 46,050 shares during the period. Pensionfund Sabic grew its holdings in Zoetis by 55.6% in the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company's stock valued at $1,825,000 after buying an additional 4,000 shares during the period. Schroder Investment Management Group grew its holdings in Zoetis by 2.6% in the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock valued at $40,036,000 after buying an additional 6,169 shares during the period. Finally, PFW Advisors LLC purchased a new position in shares of Zoetis during the 4th quarter worth about $1,764,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ZTS. Morgan Stanley cut their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Piper Sandler upped their price target on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Stifel Nicolaus cut their price objective on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Monday, April 14th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Finally, Barclays boosted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Zoetis presently has an average rating of "Buy" and a consensus target price of $214.40.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,862 shares of company stock valued at $312,254 in the last ninety days. Company insiders own 0.16% of the company's stock.

Zoetis Stock Up 0.8 %

NYSE ZTS traded up $1.22 on Wednesday, hitting $156.65. 2,926,140 shares of the stock traded hands, compared to its average volume of 2,489,611. The company has a market capitalization of $69.89 billion, a P/E ratio of 28.64, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92. The stock has a 50-day moving average of $158.81 and a 200 day moving average of $167.98. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts' consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. As a group, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.28%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.